Literature DB >> 25087755

Non-stiff anti-amphiphysin syndrome: clinical manifestations and outcome after immunotherapy.

Jangsup Moon1, Soon-Tae Lee1, Jung-Won Shin1, Jung-Ick Byun1, Jung-Ah Lim1, Yong-Won Shin1, Tae-Joon Kim1, Keon-Joo Lee1, Kyung-Il Park2, Keun-Hwa Jung1, Ki-Young Jung1, Sang Kun Lee1, Kon Chu3.   

Abstract

Amphiphysin antibody causes paraneoplastic stiff-person syndrome and can also result in a variety of neurological manifestations. Here, we investigated the clinical spectrum of 20 patients with non-stiff anti-amphiphysin syndrome and their responses to immunotherapy. The most common neurological manifestation was limbic encephalitis (n=10), followed by dysautonomia (n=9), and cerebellar dysfunction (n=6). Cancer was detected in only seven patients. Intravenous immunoglobulin or steroid treatment was effective in most patients, but three improved only after rituximab treatment. Our study suggests that anti-amphiphysin syndrome can manifest as non-stiff encephalomyelitis and is only partially associated with cancer. Active immunotherapy, including rituximab, would be beneficial.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-amphiphysin antibody; Immunotherapy; Paraneoplastic neurological syndrome; Stiff-person syndrome; rituximab

Mesh:

Substances:

Year:  2014        PMID: 25087755     DOI: 10.1016/j.jneuroim.2014.07.011

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  7 in total

Review 1.  Neuronal central nervous system syndromes probably mediated by autoantibodies.

Authors:  Aude Chefdeville; Jérôme Honnorat; Christiane S Hampe; Virginie Desestret
Journal:  Eur J Neurosci       Date:  2016-03-28       Impact factor: 3.386

Review 2.  Biomarkers for the Early Detection and Progression of Alzheimer's Disease.

Authors:  Scott E Counts; Milos D Ikonomovic; Natosha Mercado; Irving E Vega; Elliott J Mufson
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 3.  What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review.

Authors:  Sverre Georg Sæther; Morten Schou; Daniel Kondziella
Journal:  BMC Psychiatry       Date:  2017-05-03       Impact factor: 3.630

4.  The grey zone between autoimmune encephalitis and autoimmune-associated epilepsy.

Authors:  Alessandra Morano; Emanuele Cerulli Irelli; Martina Fanella; Luigi Zuliani; Anna Teresa Giallonardo; Carlo Di Bonaventura
Journal:  Epilepsia Open       Date:  2021-11-15

5.  All's well that ends well? Long-term course of a patient with anti-amphiphysin associated limbic encephalitis.

Authors:  Julia Taube; Juri-Alexander Witt; Tobias Baumgartner; Christoph Helmstaedter
Journal:  Epilepsy Behav Rep       Date:  2022-03-15

6.  Paraneoplastic syndrome or immune-related adverse event? A case of rhomboencephalitis in a patient treated with Pembrolizumab.

Authors:  G Abbadessa; G Miele; M Fratta; S Bonavita
Journal:  Acta Neurol Belg       Date:  2021-01-03       Impact factor: 2.396

7.  Effect of Immunotherapy on Seizure Outcome in Patients with Autoimmune Encephalitis: A Prospective Observational Registry Study.

Authors:  Jung-Ick Byun; Soon-Tae Lee; Keun-Hwa Jung; Jun-Sang Sunwoo; Jangsup Moon; Jung-Ah Lim; Doo Young Lee; Yong-Won Shin; Tae-Joon Kim; Keon-Joo Lee; Woo-Jin Lee; Han-Sang Lee; Jinsun Jun; Dong-Yub Kim; Man-Young Kim; Hyunjin Kim; Hyeon Jin Kim; Hong Il Suh; Yoojin Lee; Dong Wook Kim; Jin Ho Jeong; Woo Chan Choi; Dae Woong Bae; Jung-Won Shin; Daejong Jeon; Kyung-Il Park; Ki-Young Jung; Kon Chu; Sang Kun Lee
Journal:  PLoS One       Date:  2016-01-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.